Imatinib 400 MG

DRUG3 trials

Sponsors

Shanghai Zhongshan Hospital, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Centre Leon Berard

Conditions

Gastrointestinal Stromal TumorsLocally Advanced Gastrointestinal Stromal Tumor (GIST)Metastatic Gastrointestinal Stromal TumorRare TumorSurgeryUnresectable Gastrointestinal Stromal Tumor (GIST)

Phase 2

PLATFORM Study of Precision Medicine for Rare Tumors

RecruitingNCT04423185

Cancer Institute and Hospital, Chinese Academy of Medical SciencesRare Tumor

Start: 2020-08-15End: 2028-07-01Target: 770Updated: 2025-02-11

A Prospective, Randomized, Multicenter, Comparative Study of the Efficacy of Imatinib Resumption Combined With Atezolizumab Versus Imatinib Resumption Alone in Patients With Unresectable Advanced Gastrointestinal Stromal Tumors (GIST) After Failure of Standard Treatments

RecruitingNCT05152472

Centre Leon BerardLocally Advanced Gastrointestinal Stromal Tumor (GIST), Metastatic Gastrointestinal Stromal Tumor, Unresectable Gastrointestinal Stromal Tumor (GIST)

Start: 2022-01-14End: 2027-10-31Target: 110Updated: 2026-01-08

Unknown Phase

Role of Surgery in Patients With Focally Progressive Gastrointestinal Stromal Tumors (GISTs) After Imatinib Treatment

Shanghai Zhongshan HospitalGastrointestinal Stromal Tumors, Surgery

Start: 2019-07-31End: 2021-12-31Target: 92Updated: 2019-03-05

Related Papers

Platform study of genotyping-guided precision medicine for rare solid tumours: a study protocol for a phase II, non-randomised, 18-month, open-label, multiarm, single-centre clinical trial testing the safety and efficacy of multiple Chinese-approved targeted drugs and PD-1 inhibitors in the treatment of metastatic rare tumours

BMJ Open2021-06-019 citations